Published in Menopause on June 01, 2013
The Recent Review of the Genitourinary Syndrome of Menopause. J Menopausal Med (2015) 1.13
Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clin Med Insights Reprod Health (2014) 0.94
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric (2013) 0.91
The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric (2014) 0.90
Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric (2014) 0.89
The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause (2016) 0.83
Sexual health as a survivorship issue for female cancer survivors. Oncologist (2014) 0.82
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health (2013) 0.79
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med (2015) 0.78
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause (2017) 0.76
Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause (2015) 0.76
Postmenopausal dyspareunia: has the Food and Drug Administration really helped? Menopause (2013) 0.76
Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene. Ther Clin Risk Manag (2016) 0.75
Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. Int J Mol Sci (2013) 0.75
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause (2015) 0.75
A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review. Maturitas (2016) 0.75
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Womens Health (2016) 0.75
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging (2014) 0.75
The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk. Endocrinol Metab Clin North Am (2015) 0.75
Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric (2015) 0.75
A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol (2017) 0.75
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy. J Menopausal Med (2017) 0.75
Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study. Biomed Res Int (2017) 0.75
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause (2010) 1.80
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med (2005) 1.72
Assessment of vulvodynia symptoms in a sample of US women: a prevalence survey with a nested case control study. Am J Obstet Gynecol (2007) 1.63
Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age. Menopause (2005) 1.56
Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol (2006) 1.47
Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age. Menopause (2007) 1.46
The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med (2008) 1.44
Economic burden of endometriosis. Fertil Steril (2006) 1.43
Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Menopause (2011) 1.40
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation (2005) 1.34
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception (2005) 1.12
Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health (2013) 1.07
Sexual well-being, happiness, and satisfaction, in women: the case for a new conceptual paradigm. J Sex Marital Ther (2008) 1.04
One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause (2013) 1.03
Family planning attitudes of medically underserved Latinas. J Womens Health (Larchmt) (2007) 1.03
Current overview of the management of urogenital atrophy in women with breast cancer. Breast J (2011) 0.94
Current issues and available options in combined hormonal contraception. Contraception (2011) 0.93
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric (2013) 0.91
Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas (2013) 0.90
Lifelong menstrual histories are typically erratic and trending: a taxonomy. Menopause (2007) 0.90
Assessment of vulvodynia symptoms in a sample of U.S. women: a follow-up national incidence survey. J Womens Health (Larchmt) (2008) 0.88
The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas (2009) 0.86
Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med (2012) 0.86
Vulvovaginal atrophy: new and upcoming approaches. Menopause (2009) 0.84
Vulvovaginal atrophy: current and future therapies (CME). J Sex Med (2010) 0.84
The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause (2016) 0.83
Nanoparticle delivery for transdermal HRT. Maturitas (2012) 0.83
The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported. Fertil Steril (2006) 0.83
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J (2009) 0.82
Maximizing health in menopausal women with disabilities. Menopause (2002) 0.82
Osteoarthritis and osteoporosis in postmenopausal women: clinical similarities and differences. Menopause (2004) 0.81
Nanoparticle delivery for transdermal HRT. Nanomedicine (2012) 0.80
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause (2017) 0.80
The evolutionary origin and significance of menopause. Menopause (2011) 0.78
A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. Menopause (2004) 0.78
Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol (2011) 0.78
Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther (2006) 0.77
Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response. Contemp Clin Trials (2013) 0.77
In vitro effect of gonadotropin-releasing hormone agonist on natural killer cell cytolysis in women with and without endometriosis. Am J Obstet Gynecol (2004) 0.76
Female sexual well-being scale (FSWB scale): development and psychometric validation in sexually functional women. J Sex Med (2009) 0.76
Stopping menopausal hormone therapy: if breast cancer really decreased, why did colorectal cancer not increase? Maturitas (2012) 0.76
Recurrent vulvar itching. Obstet Gynecol (2005) 0.75
Towards a better understanding and management of pain: a public health mandate. J Womens Health (Larchmt) (2011) 0.75
Challenge of conducting a multicenter clinical trial: experience in commencing a vulvodynia research protocol. J Womens Health (Larchmt) (2013) 0.75
Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol (2003) 0.75
Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Menopause (2017) 0.75
Interpreting studies of nutritional prevention: a perspective using calcium as a model. J Womens Health (Larchmt) (2005) 0.75
Clinical trials in menopause. Menopause (2017) 0.75
To the Editor. Menopause (2020) 0.75
A sex-specific dose-response curve for testosterone: could excessive testosterone limit sexual interaction in women? Menopause (2017) 0.75
Osteoporosis: screening and treatment in women. Clin Obstet Gynecol (2012) 0.75
Implementing a successful clinical development program for female sexual dysfunctions (aka how to navigate a regulatory minefield). Maturitas (2011) 0.75